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ABSTRACT
Lung function decline is a well-recognized occurrence after myeloablative hematopoietic stem cell transplan-
tation (HCT) that has not been studied after nonmyeloablative conditioning regimens. We examined the lung
function of patients before and after 2-Gy total body irradiation–based nonmyeloablative and myeloablative
preparative regimens. Before HCT, at day 100, and 1 year after HCT, nonmyeloablative patients had lower
1-second forced expiratory volume (FEV1), forced vital capacity, total lung capacity, residual volume, and
carbon monoxide diffusion capacity. However, after transplantation, the risk for experiencing a >20% per year
decrease of FEV1 was significantly lower for nonmyeloablative than myeloablative patients >50 years of age
(odds ratio, 0.3; 95% confidence interval, 0.1-0.8; P .01). Lower pretransplantation FEV1 was associated with
a higher mortality rate for both groups, with the highest mortality risk among patients with a pretransplan-
tation FEV1 <60% (nonmyeloablative: hazard ratio, 3.9; 95% confidence interval, 1.9-8.0; myeloablative:
hazard ratio, 7.2; 95% confidence interval, 2.5-21.2). These results suggest that despite having worse lung
function, patients who receive the 2-Gy total body irradiation–based nonmyeloablative regimen will likely
experience less pulmonary toxicity than patients who receive a myeloablative regimen, and this may have
important clinical implications when deciding on a conditioning regimen for patients >50 years of age with
compromised pretransplantation lung function.
© 2005 American Society for Blood and Marrow Transplantation
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eNTRODUCTION
Decline in lung function after myeloablative he-
atopoietic stem cell transplantation (HCT) has long
een recognized as a signiﬁcant complication of this
otentially life-saving procedure. Although some pa-
ameters of lung function, such as lung volume and
iffusion capacity, can decline during the early post-
CT period, these abnormalities are usually partially
eversible within the ﬁrst 2 years after HCT [1,2] and
re associated with only a modest increase in mortality
isk [3]. However, decreases in spirometric measure-
ents after HCT, such as the 1-second forced expi-
atory volume (FEV1), are associated with increased
ortality [4,5], with an attributable adjusted 3-year c
88ortality rate of 22% among patients who survive at
east 1 year after HCT. Although the most commonly
ssociated risk factor for lung function decline has
een graft-versus-host disease (GVHD), some studies
ave suggested that aspects of the myeloablative pre-
arative regimen may contribute to accelerated lung
unction decline [6,7]. However, analyses of different
hemotherapeutic and irradiation regimens for my-
loablative HCT have not consistently found associ-
tions with more rapid lung function decline [5,8-11].
Over the last several years, nonmyeloablative
CT has become an accepted alternative for the
reatment of patients considered ineligible for a my-
loablative conditioning regimen because of older age,
omorbid illnesses, or more advanced disease [12-18].
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Lung Function after Nonmyeloablative HCT
Bside from the beneﬁts of the graft-versus-tumor ef-
ect, clinical evidence of less treatment-related toxicity
nd fewer complications has been accumulating over
he last several years. The nonmyeloablative regimen
f 2 Gy of total body irradiation (TBI) with or without
udarabine has been associated with a delayed onset
nd lower incidence of acute GVHD [19], a lower
ncidence of idiopathic pneumonia syndrome [20], and
lower incidence of jaundice, and no cases of hepatic
eno-occlusive disease have been described [21]. In-
ectious complications such as bacterial infections, cy-
omegalovirus infections, and invasive fungal infec-
ions are delayed in onset but have no difference in
ncidence [22-25]. On the basis of these data, we
ypothesized that the reduction in toxic effects of this
onmyeloablative regimen may also be associated with
ess lung function decline after HCT. We performed
longitudinal analysis of the changes in lung function
fter nonmyeloablative and myeloablative HCT to
haracterize the lung function of nonmyeloablative
atients before HCT, to compare the posttransplan-
ation changes in these patients’ lung function with
hose in myeloablative patients, and to determine the
ifferences in the effect of lung function on the risk
or mortality.
ETHODS
atient Selection
This was a retrospective analysis of data collected
rospectively on all nonmyeloablative HCT recipients
t the Fred Hutchinson Cancer Research Center be-
ween December 1, 1997, and January 1, 2003. Be-
ause patients undergoing nonmyeloablative HCT are
ypically older, we attempted to select age-matched
yeloablative HCT recipients at a ratio of 1 nonmy-
loablative patient to 2 myeloablative patients from
he same time period. When an age-matched control
atient was not available, a patient closest in age was
elected. Given the potential for inaccurate pulmonary
unction measurements in pediatric patients, patients
ho were 15 years old were excluded (11 patients).
ifteen patients without pretransplantation pulmo-
ary function tests (PFTs) were also excluded.
atient Characteristics
Patients were HLA-matched for HLA-A, -B, and
C by intermediate-resolution DNA typing to a level
t least as sensitive as serology and for -DRB1 and
DQB1 by high-resolution techniques [26]. All pa-
ients in the nonmyeloablative group received 2 Gy of
BI with or without ﬂudarabine (30 mg/m2 body-
urface area per day for 3 consecutive days) and with
r without preceding autologous HCT. All patients in
he myeloablative group received either non-TBI–
ased or TBI-based regimens [19]. No patients in the b
B&MTyeloablative group had a prior autologous or alloge-
eic transplantation. The non-TBI regimens included
ither busulfan (4 mg/kg/d for 4 consecutive days) and
yclophosphamide (60 mg/kg/d for 2 consecutive
ays) or targeted busulfan (4 mg/kg/d for 4 consecu-
ive days; target of 600-900 ng/mL) and ﬂudarabine
30 mg/m2 body-surface area per day for 4 consecutive
ays). The TBI-based regimens included cyclophos-
hamide (60 mg/kg/d for 2 consecutive days) and
ractionated TBI (12 Gy). Donor lymphocyte infu-
ion (DLI) was a treatment option for patients without
VHD whose underlying disease relapsed or pro-
ressed. GVHD grading has been described in detail
reviously [19].
ulmonary Function Testing
All PFTs were performed at the Fred Hutchinson
ancer Research Center according to the American
horacic Society guidelines [27] by using the Sensor-
edics V-Max 22 with Autobox 6200 (Sensormedics
o., Yorba Linda, CA). All pulmonary function values
ere expressed as a percentage of the predicted nor-
al values. Published equations for adults were used
o determine predicted values of FEV1, forced vital
apacity, total lung capacity, residual volume, and car-
on monoxide diffusion capacity (Dlco) [28,29]. If a
ronchodilator was administered, then the postbron-
hodilator values were used for analysis.
PFTs were routinely performed before HCT
baseline) and at 100 days (80  20 days) and 1 year
365  100 days) after HCT. Additional PFTs were
btained according to clinical suspicion or indication.
he rate of lung function decline between 2 time
oints was determined by calculating the annualized
ate of decline for the FEV1 by using the appropriate
FTs (see Statistical Methods).
tatistical Methods
All statistical analyses were performed with Stata
.0 (Stata Corp., College Station, TX). Two-sided
values .05 were considered statistically signiﬁcant.
or univariate analyses, 2 tests of independence were
erformed. A least-squares regression line was used to
stimate the overall annualized rate of FEV1 decline
nd the annualized rate of FEV1 decline from baseline
o day 100 and from baseline to 1 year. All PFTs
btained after HCT were used to calculate the overall
ate of FEV1 decline after HCT. Lung-function pa-
ameters were considered as categorical variables in
he analyses. A multivariable polytomous regression
odel, adjusting for covariates previously determined
o be signiﬁcant risk factors for the development of
igniﬁcant airﬂow obstruction [5], was used to deter-
ine the association between the rate of lung function
ecline and conditioning regimen and the association
etween the rate of lung function decline and TBI
289
e
t
C
m
d
c
a
R
L
e
t
o
o
h
i
b
n
t
1
e
s
y
t
(
d
T
t
a
(
s
t
t
T
A
S
U
D
S
C
D
G
E
C
*
†
‡
§
J. W. Chien et al.
2xposure. The Kaplan-Meier method and log-rank
est were used to estimate overall survival [30]. The
ox proportional hazard model was used to estimate
ortality risk, adjusting for other potential causes of
eath after HCT, with disease relapse and acute and
hronic GVHD considered as time-dependent covari-
tes when indicated.
ESULTS
ung Function at Baseline, Day 100, and 1 Year
There were 219 nonmyeloablative and 427 my-
loablative patients in this analysis. Table 1 outlines
he clinical characteristics of these patients. Despite
ur attempt to age-match the patients, the median age
f the nonmyeloablative patients was still signiﬁcantly
igher than that of the myeloablative patients. The
ncidence of acute and chronic GVHD was compara-
able 1. Patient Characteristics*
Variable
Nonmye
(n 
ge at transplantation (y)† 54.0
<40 28
40-50 51
50-60 80
>60 60
ex match (recipient:donor)
F:F 39
F:M 47
M:M 68
M:F 65
nderlying diagnosis
Acute leukemia 30
Chronic myelogenous leukemia 15
Lymphoma/CLL/multiple myeloma 126
MDS/MPD 33
Other‡ 15
onor
Related 134
Unrelated 85
tem cell source
Bone marrow 13
Peripheral blood 204
Other§ 1
onditioning
Myeloablative
No TBI
Yes TBI
Nonmyeloablative
2 Gy TBI 179
2 Gy TBI  autologous
transplant 40
onor lymphocyte infusion 24
rade III-IV acute GVHD 39
xtensive clinical chronic GVHD 135
LL indicates chronic lymphatic leukemia; MDS, myelodysplastic
GVHD, graft-versus-host disease; NE, not evaluated.
Data are n (%) unless otherwise indicated.
Median (range).
Includes renal cell carcinoma and aplastic anemia.
Includes cord blood and cord blood with or without bone marrow or pe
90le between groups. Signiﬁcantly more patients in the
onmyeloablative group received DLI.
Nonmyeloablative and myeloablative patients had
he same median number of PFTs (n  3; range,
-10). However, the mean follow-up time for nonmy-
loablative patients (1.5  1.2 years) was signiﬁcantly
horter than for myeloablative patients (2.5  1.6
ears; P  .001). Distribution of the pretransplanta-
ion, day 100, and 1-year pulmonary function values
80%, 70%-80%, 60%-70%, and 60% of pre-
icted, respectively) are summarized in Table 2.
here were proportionally fewer nonmyeloablative
han myeloablative patients in the 80% category for
ll pulmonary function parameters at all 3 time points
except for the 1-year Dlco). These differences were
tatistically signiﬁcant for forced vital capacity at all
ime points, for FEV1 at baseline and day 100, and for
otal lung capacity and Dlco at baseline only. There
ive Myeloablative
(n  427) P Value
46.6 (17-66) <.001
56 (13)
221 (52)
131 (31)
19 (4)
103 (24) .10
110 (24)
121 (28)
101 (24)
129 (30) <.001
159 (37)
18 (4)
110 (26)
11 (3)
243 (57) .30
184 (43)
234 (55) <.001
185 (43)
5 (1)
233 (55) NE
194 (45)
11 (3) <.001
90 (21) .20
308 (72) .10
e; MPD, myeloproliferative disorder; TBI, total body irradiation;loablat
219)
(17-73)
(13)
(23)
(37)
(27)
(18)
(21)
(31)
(30)
(14)
(7)
(58)
(15)
(7)
(61)
(39)
(6)
(94)
(<1)
(82)
(18)
(11)
(18)
(78)
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Lung Function after Nonmyeloablative HCT
Bere no signiﬁcant differences in the residual volume
t all 3 time points. Univariate analysis demonstrated
hat nonmyeloablative patients who had a previous
utologous transplantation or previous chemothera-
eutic treatment were not more likely to have worse
ung function (measured by any of the pulmonary
arameters) at any of the time points.
ate of Lung Function Decline after HCT
The rate of lung function decline, as measured by
he annualized rate of FEV1 decrease, has been dem-
nstrated to be signiﬁcantly associated with an in-
rease in mortality risk [4,5]. Therefore, we examined
he annualized rate of FEV1 decline for the time
eriod from baseline to day 100 after HCT, baseline
o 1 year after HCT, and the overall follow-up period
igure 1. Annualized rate of FEV1 decline during 3 time intervals
before transplantation to day 100 after transplantation, before
ransplantation to 1 year after transplantation, and overall follow-up
ime after transplantation) for nonmyeloablative and myeloablative
egimens. Before transplantation to day 100, P  .001; before
ransplantation to 1 year, P  .40; overall, P  .02.after HCT. In Figure 1, the rate of FEV1 decline forT
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2ach interval is categorized as 5%, 5% to 10%, 10%
o 20%, or 20% per year. There were proportion-
lly more nonmyeloablative than myeloablative pa-
ients in the 5% per year group for all 3 time
ntervals (baseline to day 100: 58% versus 33%, P 
001; baseline to 1 year: 62% versus 54%, P  .30;
verall: 57% versus 51%, P  .02). Independent uni-
ariate analysis revealed that a lower FEV1 at the
eginning of each interval was not associated with a
aster rate of FEV1 decline during any of these inter-
als.
The risk for signiﬁcant FEV1 decline during the 3
ime periods was assessed in separate multivariable
odels that included risk factors previously identiﬁed
s associated with the development of airﬂow obstruc-
ion[5]. These risk factors included lung function at
aseline as measured by FEV1, presence of grade III to
V acute GVHD, and presence of clinical extensive
hronic GVHD. Because of the signiﬁcant difference
n follow-up time between the 2 groups, follow-up
ime was included in the models where indicated.
hese models were also stratiﬁed by age at HCT
ecause of its potential confounding effect on the rate
f lung function decline and choice of conditioning
egimen. Patients 50 years of age who received the
able 4. Risk of Signiﬁcant Lung Function Decline after Transplantati
Conditioning Regimen
5%-10%/y
OR (95% CI) P Value
ransplantation to day 100
2 Gy Referent
No TBI 1.9 (0.6-5.9) .30
>12 Gy TBI 0.4 (0.04-3.2) .40
ransplantation to 1 y
2 Gy Referent
No TBI 1.8 (0.5-6.6) .40
>12 Gy TBI 3.2 (0.7-13.5) .10
verall
2 Gy Referent
No TBI 0.6 (0.3-1.6) .30
>12 Gy TBI 0.7 (0.2-2.0) .50
R indicates odds ratio; CI, conﬁdence interval; TBI, total body i
he polytomous logistic model contained the following covariates:
able 3. Risk of Lung Function Decline among Patients 50 Years of
Rate of FEV1
Decline
Before Transplantation to
Day 100 B
OR (95% CI) P Value O
5%/y Referent
%-10%/y 0.7 (0.3-2.2) .60 0
0%-20%/y 0.3 (0.1-0.7) .007 0
20%/y 0.4 (0.2-0.7) .003 0
R indicates odds ratio; CI, conﬁdence interval.
olytomous models include the following covariates where indicate
FEV1, presence of grade III to IV acute GVHD, presence of c
comparison to myeloablative conditioning regimen.FEV1, presence of grade III to IV acute GVHD, presence of clinical e
92onmyeloablative regimen had a lower risk of experi-
ncing an FEV1 decline of 20% per year during all
time periods (Table 3). There was no signiﬁcant
ssociation between the nonmyeloablative regimen
nd the decrease in risk for signiﬁcant FEV1 decline
mong patients who were 50 years of age.
To further explore potential reasons for this
lower rate of FEV1 decline among nonmyeloablative
ransplantations, we assessed variables that were sig-
iﬁcantly different from the myeloablative cohort.
nivariate analysis revealed no association between
he rates of lung function decline and disease risk,
nderlying diagnosis, stem cell source, or DLI.
mong the nonmyeloablative patients, there were no
ssociations of the rate of FEV1 decline during any of
he 3 time intervals with a previous autologous trans-
lantation or the number of chemotherapeutic regi-
ens received before HCT. Both cohorts were then
ombined and stratiﬁed according to age to determine
hether there was a signiﬁcant association of the rate
f FEV1 decline during each time interval with the
onditioning regimen. This revealed a signiﬁcantly
igher risk for a 20% per year decrease of FEV1
mong patients 50 years of age who received my-
loablative regimens, whether the myeloablative reg-
Total Body Irradiation Dose among Patients 50 Years of Age
10%-20%/y >20%/y
OR (95% CI) P Value OR (95% CI) P Value
Referent Referent
4.7 (1.7-13.6) .004 2.6 (1.3-5.2) .01
2.6 (0.7-9.4) .10 2.9 (1.3-3.6) .009
Referent Referent
1.8 (0.6-5.7) .30 6.8 (1.1-42.8) .04
3.0 (0.8-10.8) .10 7.5 (0.9-59.8) .06
Referent Referent
3.6 (1.2-10.0) .01 2.5 (1.01-6.4) .05
2.6 (0.7-9.1) .10 3.9 (1.3-11.4) .01
on.
splantation lung function measured by the percentage of predicted
ceiving Nonmyeloablative Conditioning Regimens
Transplantation to 1 y Overall
% CI) P Value OR (95% CI) P Value
ent Referent
1.4) .20 1.5 (0.7-3.3) .30
1.3) .20 0.3 (0.1-0.8) .02
-0.99) .05 0.3 (0.1-0.8) .01
ransplantation lung function measured by percentage of predicted
extensive chronic GVHD, and follow-up time. Odds ratios are inon and
rradiati
pretranAge Re
efore
R (95
Refer
.5 (0.2-
.5 (0.2-
.2 (0.04
d: pret
linicalxtensive chronic GVHD, and follow-up time.
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Lung Function after Nonmyeloablative HCT
Bmen was TBI based or non–TBI based (Table 4).
his association was not observed among patients
50 years of age.
ortality Analysis
Overall, there were 266 deaths: 111 (50%) among
he nonmyeloablative patients and 155 (35%) among
igure 2. Kaplan-Meier survival curves for all patients combined
P .001), nonmyeloablative patients (P .004), and myeloablative
atients (P  .001), based on pretransplantation FEV1 categories.
olid line indicates FEV1 80% (all patients, n  543; nonmyeloa-
lative patients, n  148; myeloablative patients, n  395), dashed
ine, FEV1 70% to 80% (all patients, n  61; nonmyeloablative
atients, n  41; myeloablative patients, n  20), dotted line, FEV1
0% to 70% (all patients, n  23; nonmyeloablative patients, n 
5; myeloablative patients, n  8), dashed and dotted line, FEV1
60% (all patients, n  19; nonmyeloablative patients, n  15;
yeloablative patients, n  4).he myeloablative patients. Separate Kaplan-Meier es- o
B&MTimates of survival were generated to determine the
urvival rates according to baseline FEV1 and condi-
ioning regimen (Figure 2). The survival rate was
rogressively lower with worse lung function at base-
ine. When all patients were considered together, the
-year survival rate for patients with baseline FEV1
60% was approximately 25%. Subanalysis indicated
hat the survival rate for the lowest FEV1 group was
orse for the myeloablative than the nonmyeloabla-
ive group. No myeloablative patients with a baseline
EV1 60% survived beyond 2 years. In a multivari-
ble Cox proportional hazard model that adjusted for
ge at HCT, underlying diagnosis, acute and chronic
VHD, and disease relapse, the risk of mortality
ncreased signiﬁcantly in a stepwise fashion with suc-
essively lower categories of baseline FEV1 (Table 5).
hen the nonmyeloablative and myeloablative pa-
ients were analyzed separately, this trend was also
resent, and the risk of death was highest for myelo-
blative patients with a baseline FEV1 60% (myelo-
blative: hazard ratio, 7.2; P  .001; nonmyelo-
blative: hazard ratio, 3.9; P  .001). However, these
isks were not signiﬁcantly different between these 2
roups (P  .60).
ISCUSSION
The nonmyeloablative regimen was originally de-
igned to reduce toxicities while optimizing graft-
ersus-tumor effects [31]. By comparing these patients
ith patients who received myeloablative regimens,
e found that nonmyeloablative patients were more
ikely to have worse lung function overall but were less
ikely to experience rapid lung function decline. Our
ndings support the notion, ﬁrst suggested by Fukuda
t al. [20], that the ﬂudarabine/2-Gy TBI regimen
ay result in less pulmonary toxicity.
Patients who are considered for a nonmyeloabla-
ive HCT are generally older, have more comorbid
llnesses, have advanced malignant disease, and/or
ave more prior chemotherapy and radiation therapy
14,32,33]. Thus, there are 3 potential explanations
or the lower lung function observed among nonmy-
loablative patients. First, up to 10% to 15% of the
onmyeloablative cohort had previous chest irradia-
ion, which may have resulted in pulmonary toxicity.
owever, because these data were not detailed
nough for all nonmyeloablative patients, we were not
ble to include chest irradiation in the analysis. Sec-
nd, although health status only weakly correlates
ith spirometry [34-36], a worse health status may
artially explain why the nonmyeloablative patients,
ho were likely ineligible for a myeloablative regimen
ecause of age and/or comorbidities, had worse lung
unction. Finally, the nonmyeloablative patients were
n average 8 years older than the myeloablative pa-
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2ients. Thus, the lower lung function among the non-
yeloablative cohort may be due to several physio-
ogic factors, such as decreased lung elastic recoil
37,38] and declining inspiratory and expiratory mus-
le strength [39,40], that have been identiﬁed as com-
on causes of airﬂow limitations in the asymptomatic
eriatric population [41]. On the basis of these poten-
ial explanations, our data indicating that nonmyelo-
blative patients tend to have worse lung function than
yeloablative patients were not unexpected.
Despite having worse lung function, nonmyelo-
blative patients experienced slower lung function de-
line than the myeloablative patients. Speciﬁcally, our
ata demonstrate that the intensity of the condition-
ng regimen has the greatest effect on patients 50
ears of age; older patients were at a signiﬁcantly
ncreased risk for a 20% per year decline in FEV1
fter myeloablative regimens versus after the 2-Gy
BI regimen. When these ﬁndings are interpreted
n conjunction with previous studies that have com-
ared the posttransplantation complications of non-
yeloablative and myeloablative regimens, they
upport the hypothesis that the 2-Gy TBI–based
onmyeloablative regimen is less likely than my-
loablative regimens to cause pulmonary toxicity.
his observation may have important implications
or selecting a preparative regimen for older indi-
iduals undergoing HCT.
Our study had 2 clinically important ﬁndings re-
arding baseline lung function and mortality risk.
irst, it was clear that regardless of conditioning reg-
men, the pretransplantation FEV1 directly correlated
ith survival rates. Patients in the60% category had
he lowest survival rate. This was quantiﬁed in the
ultivariable analysis, in which stepwise increases in
he hazard ratio were observed for successively worse
EV1 categories. Second, despite a higher all-cause
ortality rate among the nonmyeloablative patients
50% versus 35%), which can be attributed to pre-
ransplantation comorbidities, disease relapse [32,33],
nd pretransplantation lung function that was worse
han that of myeloablative patients, nonmyeloablative
able 5. Adjusted Mortality Risks after Transplantation Based on Pret
FEV1
Overall
HR (95% CI) P Value HR
80% Referent — Re
0%-80% 1.7 (1.2-2.5) .004 1.9 (
0%-70% 2.7 (1.5-4.6) <.001 2.8 (
60% 4.2 (2.4-7.3) <.001 3.9 (
R indicates hazard ratio; CI, conﬁdence interval.
ung function at each time point was assessed in separate models.
disease risk. Presence of grade III to IV acute GVHD, cli
time-dependent covariates.
These values were not signiﬁcantly different (P  .60).atients with a FEV1 60% before HCT had a better i
94-year survival rate than myeloablative patients with
imilar lung function (30% versus 0%) and had a
ower hazard ratio in the multivariable model. Al-
hough these risks were not signiﬁcantly different be-
ween the 2 groups, these data suggest that pretrans-
lantation lung function should be considered in the
retransplantation comorbidity assessment when con-
idering a potential candidate for a myeloablative al-
ogeneic HCT.
Our data should be interpreted with awareness of
everal important issues. First, the results of this study
re applicable only to the 2-Gy TBI with or without
udarabine nonmyeloablative regimen. Because this is
onsidered to be one of the less intense nonmyeloab-
ative conditioning regimens [31], similar results may
ot be observed with other, more intense, regimens.
econd, this study is subject to the “healthy survivor
ffect” [42] common to all studies involving pulmo-
ary function. Because PFTs can be obtained only if a
atient is alive, our results do not reﬂect lung function
ecline among patients who died without a follow-up
FT. Unfortunately, this is a limitation inherent in all
tudies of pulmonary function that cannot be reme-
ied in a retrospective analysis. Third, although PFTs
re conducted according to protocol on day 100 and at
year, patients are more likely to have more PFTs if
hey have a respiratory complaint or problem. We
ccounted for this by including the follow-up time in
ur multivariable analyses.
In summary, nonmyeloablative patients tended
o have worse lung function than myeloablative pa-
ients before and after HCT. However, despite hav-
ng worse lung function, nonmyeloablative patients
xperienced a signiﬁcantly slower rate of lung func-
ion decline after HCT and had a lower mortality
isk based on pretransplantation lung function.
hen these data are interpreted in conjunction
ith previous studies that have compared the post-
ransplantation complications of nonmyeloablative
nd myeloablative regimens, they suggest that the
-Gy TBI–based nonmyeloablative conditioning
egimen may be less likely than myeloablative reg-
tation Percentage of Predicted FEV1
yeloablative Myeloablative
I) P Value HR (95% CI) P Value
Referent
) .01 2.0 (1.04-3.9) .04
) .003 2.2 (0.8-6.2) .10
)* <.001 7.2 (2.5-21.2)* <.001
dels included the following covariates: age at transplantation and
xtensive chronic GVHD, and disease relapse were included asransplan
Nonm
(95% C
ferent
1.1-3.0
1.4-5.7
1.9-8.0
All mo
nical emens to cause pulmonary toxicity.
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